Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression

The elongation of long-chain fatty acids family member 6 (Elovl6) is a key enzyme in lipogenesis that catalyzes the elongation of saturated and monounsaturated fatty acids. Insulin resistance involves upregulation of Elovl6, which has been linked to obesity-related malignancies, including hepatocell...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2018-04, Vol.8 (1), p.6586-8, Article 6586
Main Authors: Su, Yu-Chu, Feng, Yin-Hsun, Wu, Hung-Tsung, Huang, Yao-Shen, Tung, Chao-Ling, Wu, Pensee, Chang, Chih-Jen, Shiau, Ai-Li, Wu, Chao-Liang
Format: Article
Language:English
Subjects:
13/1
13/51
13/95
14/34
38
38/1
42/41
631/67/1504/1610/4029
631/67/395
64/60
AKT protein
Cell activation
Cell proliferation
Elongation
Fatty acids
Hepatocellular carcinoma
Humanities and Social Sciences
Insulin
Lipogenesis
Liver cancer
Medical prognosis
multidisciplinary
Science
Science (multidisciplinary)
Therapeutic applications
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The elongation of long-chain fatty acids family member 6 (Elovl6) is a key enzyme in lipogenesis that catalyzes the elongation of saturated and monounsaturated fatty acids. Insulin resistance involves upregulation of Elovl6, which has been linked to obesity-related malignancies, including hepatocellular carcinoma (HCC). However, the role of Elovl6 in cancer progression remains unknown. In this study, we analyzed the expression of Elovl6 in 61 clinical HCC specimens. Patients with Elovl6 high-expressing tumors were associated with shorter disease-free survival and overall survival compared to those with Elovl6 low-expressing tumors. Knockdown of Elovl6 in HCC cells reduced cell proliferation and Akt activation, as well as sensitivity to fatty acids. Inhibition of Elovl6 reduced tumor growth and prolonged survival in mice bearing tumors. Taken together, our results indicate that Elovl6 enhances oncogenic activity in liver cancer and is associated with poor prognosis in patients with HCC. Elovl6 may be a therapeutic target for HCC; thus, further studies to confirm this strategy are warranted.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-24633-3